Protopic Safety Study Published in JAAD
A big-data study that examined the concern about lymphoma with Protopic ointment, used to treat vitiligo and atopic dermatitis, has been published in the Journal of the American Academy of Dermatology (JAAD). Dr. Jung Min Bae led the study, which analyzed 19 years of data from 33,703 patients at 20 university hospitals nationwide.
The safety of Protopic use, which had raised fears about causing lymphoma, has been demonstrated through analysis of big data from patients at 20 university hospitals nationwide.
Protopic ointment, a topical immunomodulator widely used to treat vitiligo and atopic dermatitis. However, for a long time, a concern mixed with hearsay that using this ointment could cause skin cancer or lymphoma has made patients anxious. Dr. Jung Min Bae led a large-scale big-data study with 28 university professors nationwide to put an end to this vague fear.
By tracking and analyzing data from 33,703 patients treated at 20 university hospitals over 19 years, the study fully demonstrated that the ointment does not increase the risk of cancer. As a result, the findings were published in the Journal of the American Academy of Dermatology (JAAD), one of the world's most prestigious dermatology journals, earning recognition from the academic community.
Transforming patients' vague fears into reassurance through thorough evidence-based medicine is the mission of a physician that Heal House upholds.
Was this article helpful?
